Mechanism of Action

Reduced Intracellular Iron → KDM Modulation → Restoration of Gene Regulation → Tumor-Suppressor Activity
Telomir-Zn is designed to modulate intracellular iron and copper balance, influencing epigenetic pathways associated with tumor growth and treatment resistance.

Telomir-Zn

Telomir-Zn: Epigenetic Reprogramming via Metal Homeostasis

MECHANISM

Telomir-Zn modulates intracellular iron and copper balance, reducing the activity of key epigenetic enzymes associated with tumor growth. This may help restore tumor-suppressor pathways that are frequently silenced in cancer.

WHAT MAKES IT DIFFERENT

Rather than directly targeting a single epigenetic enzyme, Telomir-Zn is designed to influence multiple iron-dependent epigenetic pathways through modulation of intracellular metal balance.

REGULATORY STATUS

Advancing toward Phase 1/2 initiation in TNBC

Significant Anti-Cancer Activity

Significant Anti-Cancer Activity in BT 549 Breast Cancer Model

Zebrafish xenograft | Triple-negative breast cancer | Oral administration daily x3 days

Study Design

  • BT549 human triple-negative breast cancer cells in zebrafish xenograft
  • Telomir-Zn administered orally daily for 3 days to zebrafish embryos
  • Comparator: Paclitaxel (standard-of-care chemotherapy)

Key Results

  • Tumor volume suppression comparable to Paclitaxel at equimolar doses
  • Additive anti-tumor effect when combined with Paclitaxel
  • No dose-limiting toxicity or off-target effects observed

Significance

  • First oral small molecule with comparable efficacy to IV chemotherapy in TNBC
  • Additive effects enable potential combination therapy strategies

Telomir-Zn

Telomir-ZN Suppresses Tumor Growth & Metastasis

Zebrafish xenograft | Triple-negative breast cancer | Oral administration daily x3 days

Study Design

  • HC1806 chemo-resistant human triple-negative breast cancer cells in zebrafish xenograft
  • Telomir-Zn administered orally daily for 3 days to zebrafish embryos
  • Comparator: Paclitaxel (standard-of-care chemotherapy)

Key Results

  • Significant tumor reduction at 3 µM and 10 µM Telomir-Zn (p<0.05 and p<0.001)
  • Additive anti-tumor effect when combined with Paclitaxel vs. either monotherapy alone
  • No dose-limiting toxicity or off-target effects observed

Significance

  • Telomir-Zn is the first oral agent to demonstrate both primary tumor suppression and statistically significant reduction of metastatic dissemination in a chemotherapy-resistant TNBC model — a finding not observed with Paclitaxel alone